These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 25421015)

  • 41. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
    Watada H; Shiramoto M; Ueda S; Tang W; Asano M; Thorén F; Kim H; Yajima T; Boulton DW; Araki E
    Diabetes Obes Metab; 2019 Apr; 21(4):876-882. PubMed ID: 30499157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.
    Inagaki N; Kondo K; Yoshinari T; Ishii M; Sakai M; Kuki H; Furihata K
    Clin Drug Investig; 2014 Oct; 34(10):731-42. PubMed ID: 25200141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
    Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
    Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
    Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
    Oliva RV; Bakris GL
    J Am Soc Hypertens; 2014 May; 8(5):330-9. PubMed ID: 24631482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
    Nishimura R; Tanaka Y; Koiwai K; Inoue K; Hach T; Salsali A; Lund SS; Broedl UC
    Cardiovasc Diabetol; 2015 Jan; 14():11. PubMed ID: 25633683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
    Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
    Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
    Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
    Cuypers J; Mathieu C; Benhalima K
    Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
    Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
    Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
    Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
    BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
    Gilbert RE
    Kidney Int; 2014 Oct; 86(4):693-700. PubMed ID: 24257692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.